Psychedelics., Год журнала: 2024, Номер unknown, С. 1 - 2
Опубликована: Авг. 12, 2024
Depression is a global public health challenge that represents the world's largest cause of disability, especially in context traditional treatments. One potential solution being explored psilocybin assisted psychotherapy (PAP) which shows promise for treating depression. A recent study by Rosenblat et al. explores use clinical mental care with promising results (1).
Язык: Английский
American Journal of Psychiatry, Год журнала: 2025, Номер 182(1), С. 1 - 5
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
2
Frontiers in Psychiatry, Год журнала: 2025, Номер 15
Опубликована: Янв. 7, 2025
Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased attention over the past decades. Evidence-based approaches to prevent PGD are currently scarce, not always effective. This paper introduces protocol clinical trial exploring effectiveness of Meaning Reconstruction psychotherapy approach (MR) assisted with ayahuasca, traditional indigenous medicine. The outlined is three-arm, non-randomized controlled focused on reducing normal pathological symptoms, comparing Ayahuasca-assisted MR therapy (A-MR), alone No Treatment (NT). At least 69 people who lost first-degree relative during prior year, Texas Revised Inventory score up 39 (TRIG ≥ 40), will participate in trial. Participants be allocated A-MR (n 23), 23) or NT group. Those from groups undergo therapeutic process involving 9 sessions online psychotherapy. In addition, involves 2 group ayahuasca. primary outcomes severity as measured TRIG Traumatic Self-Report (TGI-SR), administered at baseline, post-treatment, 3-month follow up. Measures quality life, post-traumatic growth, meaning-made, psychological flexibility, self-belief consistency also included. subjective effects ayahuasca acceptance-avoidance promoting assessed following administration. Finally, we analyze potential mediating effect flexibility symptoms (as TGI). first empirically examinate psychedelic-assisted grief, well processes change that may account it. https://clinicaltrials.gov, identifier NCT06150859.
Язык: Английский
Процитировано
0
Current Addiction Reports, Год журнала: 2025, Номер 12(1)
Опубликована: Фев. 19, 2025
Язык: Английский
Процитировано
0
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер unknown, С. 111333 - 111333
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Psychedelics., Год журнала: 2025, Номер unknown, С. 1 - 9
Опубликована: Апрель 29, 2025
Spiritual health practitioners (SHPs), also known as healthcare chaplains, are increasingly involved in facilitating psychedelic-assisted therapies clinical trials and community settings. Although the motivations of therapeutic to impact decision-making treatment outcomes, little research has investigated what drives SHPs pursue this work. This qualitative study examined n = 15 SHP's (60% female; M Age 46.57) who were legal administration therapy. An inductive-deductive analysis approach yielded two major themes: (1) Initial Motivation for Practicing PAT, (2) Ongoing Sources Meaning Fulfillment. The often cited personal experiences key entering field, frequently linked a significant encounter with psychedelic use. most common Fulfillment included witnessing healing others experiencing positive impacts from care. article addresses substantial role that appear play SHPs’ area practice. Such provide valuable first-hand knowledge unique phenomenology treatment, although they can potentially introduce biases reduce objectivity. Training certification guidelines set by Association Clinical Pastoral Education (ACPE) may help address these risks through heavy emphasis placed on self-literacy reflective learning components. Guided findings, we novel exercise, well several existing ACPE components support facilitators facilitators-in-training any professional background.
Язык: Английский
Процитировано
0
Child and Adolescent Psychiatry and Mental Health, Год журнала: 2025, Номер 19(1)
Опубликована: Июнь 4, 2025
Язык: Английский
Процитировано
0
Der Nervenarzt, Год журнала: 2024, Номер 95(9), С. 803 - 810
Опубликована: Авг. 28, 2024
With the discovery of antidepressive effects ketamine and increasing withdrawal pharmaceutical industry from development new psychotropic drugs, psychiatric research into clinical application hallucinogens in psychiatry has literally blossomed last two decades. Promising results for various treatment approaches with psychedelic agents, such lysergic acid diethylamide (LSD) psilocybin, dissociative as esketamine, have raised great hopes among researchers, clinicians patients recent years, so that there was already talk a era psychiatry. As one first these substances, December 2019 intranasal esketamine approved USA EU treatment-resistant depression Switzerland followed 2020. Recently, psilocybin Australia, Canada compassionate use exceptional cases depression, while large approval studies agents are currently ongoing worldwide. The medical ketamine/esketamine is considered to be safe; however, all forms it crucial importance that, addition hopes, specific challenges must also carefully assessed. Excessive expectations an insufficient risk-benefit estimation detrimental reputation treating physician. Although possible paradigm shift care mental health being discussed, this review article consciously concentrates on risks methodological weaknesses carried out far.
Язык: Английский
Процитировано
1
Acta Psychiatrica Scandinavica, Год журнала: 2024, Номер unknown
Опубликована: Дек. 3, 2024
ABSTRACT Introduction There is growing interest in the use of psychedelic‐assisted therapy (PAT) for major depressive disorder (MDD), including treatment‐resistant depression. We used randomized controlled trial (RCT) data to compare summary estimates change depression ratings with PAT versus comparator treatments MDD. also compared response and remission rates, adverse effects. Methods searched MEDLINE, EMBASE, Cochrane Central Register Controlled Trials (CENTRAL), SCOPUS from inception till April 2024. Our primary efficacy outcome was 1‐week (or nearest) between‐group ratings. Secondary outcomes were changes at days 2, 14, 42 study‐defined rates week 1 nearest). Safety reported pooled random‐effects meta‐analyses using standardized mean difference (SMD; Hedges g ) continuous risk ratio (RR) categorical outcomes. Results found 6 eligible RCTs (pooled N = 427), all on psilocybin. The SMD −0.72 [95% CI, −0.95 −0.49; I 2 17%; 5 RCTs; n 403], favouring PAT; results similar 42. [RR 3.42; 95% 2.35–4.97; 0%; 4 373] 3.66; 2.26–5.92; favored PAT. group had a small but significantly increased developing any event 1.20; 1.01–1.42; 43%; higher experiencing headache 1.78; 1.10–2.86; 52%; dizziness 6.52; 1.19–35.87; 3 269]. Low heterogeneity characterized most analyses findings sensitivity analyses. Conclusion Antidepressant effects psilocybin‐assisted are superior (with least medium effect sizes) interventions up weeks postintervention.
Язык: Английский
Процитировано
1
Journal of Psychoactive Drugs, Год журнала: 2024, Номер unknown, С. 1 - 11
Опубликована: Сен. 19, 2024
Psychedelic-assisted therapy (PAT) has shown preliminary efficacy for psychiatric and physical health conditions. Although some people report naturalistic psychedelic use with so-called "underground" practitioners, little is known about PAT that occurs outside of controlled clinical settings or perspectives these practitioners. We conducted an anonymous online survey individuals who reported providing support services (e.g. trip sitting and/or preparatory/follow-up psychotherapy) in settings. investigated demographics, including education licensing, details provided, client outcomes. Among 107 participants, 40.2% held a full in-progress license 44.9% had not obtained relevant graduate degree. Almost all participants pre-screening clients before treatment, offering preparation, integration, trip-sitting services, most employed range therapeutic modalities, centering primarily on non-directive approaches. Participants commonly consumed psilocybin, treated numerous conditions, aligning indications targeted research. Perceptions clients' symptom changes were largely positive, although small proportion worsened personality disorder symptoms. Further research delineating practitioner warranted, such work may shed light the benefits risks specific to as well inform best practices
Язык: Английский
Процитировано
0
Irish Journal of Psychological Medicine, Год журнала: 2024, Номер unknown, С. 1 - 9
Опубликована: Ноя. 7, 2024
Abstract Objectives: Understanding variations in knowledge and attitudes of psychiatrists to psilocybin therapy is important for the collective discourse about potential impact on clinical practice public health Ireland. Methods: A 28-item questionnaire was designed based previous studies distributed Ireland via online mailing lists at in-person academic events. Results: 151 completed (73.3% were under 40 years age, 76.0% trainees, 49.0% female). In total sample, 81.5% agreed that shows promise treatment psychiatric disorders 86.8% supported funding research, would be willing refer a patient if it licensed indicated, 78.1% consider themselves, indicated. Conversely, 6.6% unsafe even medical supervision, 21.9% thought potentially addictive. 15.9% sample reported least one concern including, lack robust evidence, long-term effectiveness, superiority current interventions, harmful effects, cost accessibility, impartiality. Less than half respondents felt knowledgeable (40.0%) 9.9% adequately prepared participate therapy. Consultant trended towards less optimism role bipolar depression emotionally unstable personality disorder compared trainee psychiatrists. Conclusion: Overall held positive However, there evident. Addressing gap aligning with best available evidence will key psychedelic prevail setting.
Язык: Английский
Процитировано
0